))
Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of September 23, 2024
Manage episode 442021090 series 3560281
Innhold levert av Healio. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Healio eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more. Read the full coverage here:
Blue-collar workers more likely to miss work, quit due to psoriatic arthritis
Infliximab biosimilar uptake rapidly increased only after release of a third option
National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala
Safety checklist compiles clinically important DMARD warnings in one place
Guselkumab demonstrates long-term efficacy, safety in psoriasis
References:
Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1.
Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1.
Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963.
Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.
120 episoder
Del
